Arbutus Announces 2023 Corporate Objectives and Provides Financial Update
05 janv. 2023 07h30 HE
|
Arbutus Biopharma Corporation
Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into...